MERZ PHARMA GmbH & CO. KGaA Patent applications |
Patent application number | Title | Published |
20140371260 | COMBINATION THERAPY USING 1-AMINOCYCLOHEXANE DERIVATIVES AND ACETYLCHOLINESTERASE INHIBITORS - The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine. | 12-18-2014 |
20140303246 | USE OF ADAMANTANE DERIVATIVES FOR THE TREATMENT OF ACTINIC KERATOSIS - Use of an adamantaneamine derivative for the treatment of actinic keratosis. | 10-09-2014 |
20140248332 | COMPOSITION COMPRISING AN ONION EXTRACT AND LIPOSOMES - The present invention relates to a composition comprising a first onion extract (A), and liposomes, wherein at least a portion of the onion extract is encapsulated in the liposomes. Furthermore the present invention relates to a method for preparing a composition comprising a first onion extract (A), and liposomes, wherein at least a portion of the onion extract is encapsulated in the liposomes. Further, the present invention relates to a composition comprising an onion extract (A) ( | 09-04-2014 |
20140187755 | CLOSTRIDIAL NEUROTOXINS WITH ALTERED PERSISTENCY - The invention relates to a polypeptide comprising:
| 07-03-2014 |
20140178512 | IN SITU FORMATION OF A FILLER - The present invention pertains to a method for the in situ preparation of a filler, comprising the step of applying a polyanionic biopolymer solution at an application site below the dermis of a patient for restoring volume at said application site, wherein the polyanionic biopolymer is selected from pectin and gellan. Furthermore, the present invention pertains to a kit comprising (i) a polyanionic biopolymer solution; and (ii) a solution comprising at least one divalent cation. | 06-26-2014 |
20140134643 | MEANS AND METHODS FOR THE DETERMINATION OF THE AMOUNT OF NEUROTOXIN POLYPEPTIDE AND OF ITS CATALYTIC AND PROTEOLYTIC ACTIVITIES - The present invention pertains to the field of tools for ensuring manufacture of polypeptides and quality control. Specifically, it relates to a method for determining of the amount of processed (active) Neurotoxin polypeptide in a solution comprising processed Neurotoxin polypeptide and partially processed or unprocessed Neurotoxin polypeptide. The present invention relates further to a device for determining the amount and a kit adapted to carry out the method of the present invention. | 05-15-2014 |
20140107212 | 1-AMINO-ALKYLCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF MAST CELL MEDIATED DISEASES - The present invention relates to the treatment of an individual afflicted with mast cell mediated diseases comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative. | 04-17-2014 |
20140105882 | THERAPEUTIC COMPOSITION WITH A BOTULINUM NEUROTOXIN - The present invention pertains to pharmaceutical compositions which comprise a botulinum neurotoxin from | 04-17-2014 |
20140045760 | NEUROTOXINS EXHIBITING SHORTENED BIOLOGICAL ACTIVITY - The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a Neurotoxin polypeptide exhibiting a reduced duration of biological effect in a subject, wherein the polypeptide comprises at least one degradation signal in the light chain as well as vectors and host cells comprising the polynucleotide, polypeptides encoded thereby and antibodies specifically binding to the polypeptides. Moreover, the invention relates to medicaments comprising the polynucleotides and polypeptides as well as specific therapeutic applications thereof. Furthermore, the present invention contemplates methods for the manufacture of the polypeptides and medicaments. | 02-13-2014 |
20140010803 | HIGH FREQUENCY APPLICATION OF BOTULINUM TOXIN THERAPY - The present invention relates to methods for treating diseases and disorders by administering a composition containing the neurotoxic component of a | 01-09-2014 |
20140004541 | METHOD FOR THE DETERMINATION OF BOTULINUM NEUROTOXIN BIOLOGICAL ACTIVITY | 01-02-2014 |
20130331332 | COMPOSITION COMPRISING PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-GAMMA - An injectable composition comprising peroxisome proliferator-activated receptor-gamma for subcutaneous administration and a method for improving imperfections of the skin, wherein the injectable composition is subcutaneously administered at the area of skin imperfections comprising the steps: a) identifying an area of skin imperfections, b) administering a safe and cosmetically effective amount of the composition subcutaneously to the area of skin imperfections. | 12-12-2013 |
20130296427 | NERAMEXANE FOR THE TREATMENT OR PREVENTION OF TINNITUS RELATED WITH STRESS OR ACUTE HEARING LOSS - Nerarnexane or a pharmaceutically acceptable salt thereof for use in the treatment or prevention of tinnitus, wherein said neramexane or a pharmaceutically acceptable salt thereof is administered to a patient afflicted with tinnitus caused by stress or acute hearing loss. | 11-07-2013 |
20130289090 | INDOLE DERIVATIVES AND PROCESS FOR THEIR PREPARATION - Substituted indole derivatives of formula (I) wherein the radicals have e.g. the following meaning: R | 10-31-2013 |
20130225512 | DIPEPTIDE ANALOGS FOR TREATING CONDITIONS ASSOCIATED WITH AMYLOID FIBRIL FORMATION - Dipeptide analogs comprising a tryptophan (Trp) moiety coupled to a beta-sheet breaker moiety derived from alpha-aminoisobutyric acid (Aib) are disclosed. The dipeptide analogs exhibit an improved performance in inhibiting amyloid fibril formation, as compared to previously described dipeptides. Compositions containing the dipeptide analogs and uses thereof in treating amyloid-associated diseases and disorders are also disclosed. | 08-29-2013 |
20130224248 | FORMULATION SUITABLE FOR STABILIZING PROTEINS, WHICH IS FREE OF MAMMALIAN EXCIPIENTS - A formulation free of protein which stabilizes pharmaceutical active proteins, peptides, or mixtures thereof in large scale production processes comprising a mixture of a hydrophilic polymer and a non-ionic detergent, and a mixture of a polyalcohol and a sugar. In some embodiments the polyalcohol is absent. | 08-29-2013 |
20130197053 | PHARMACEUTICAL COMPOSITION CONTAINING A TRYPTOPHAN DERIVATIVE - Pharmaceutical compositions containing a compound of formula (I) wherein the radicals denote e.g.: R | 08-01-2013 |
20130196944 | FILLER COMPOSITION COMPRISING BETA-GLUCANS - The present invention pertains to a filler composition comprising β-glucan moieties and optionally a cosmetically and/or pharmaceutically acceptable carrier. It further relates to a filler composition, wherein the β-glucan moieties are cross-linked. in one embodiment of the instant invention the filler composition is a dermal filler. In one further embodiment of the present invention the filler composition is for the treatment of wrinkles and/or folds. In another embodiment of the instant invention the filler composition is for use in the treatment of a medical condition. The filler composition provided in the present invention may further comprise one or more active pharmaceutical ingredients. Further, the present invention pertains to a process for preparing the filler composition as claimed herein. | 08-01-2013 |
20130165522 | GEL FORMULATIONS FOR THE TOPICAL USE OF 1-AMINO-ALKYLCYCLOHEXANE DERIVATIVES - This invention provides a pharmaceutical composition for topical application to the skin of a patient in need of, comprising neramexane or a pharmaceutically acceptable salt thereof, and at least one gel forming agent for the treatment or prevention of inflammatory skin diseases such as impetigo contagiosa, acne, rosacea, eczema, atopic dermatitis, contact dermatitis, seborrheic dermatitis, psoriasis, and/or oily skin. The at least one gel forming agent comprises polymers with neutral and/or positively charged polymer backbones. | 06-27-2013 |
20130158235 | SELECTIVE MANUFACTURE OF RECOMBINANT NEUROTOXIN POLYPEPTIDES - The present invention pertains to recombinant neurotoxin polypeptides and the manufacture thereof. Specifically, it relates to a polynucleotide encoding a neurotoxin polypeptide comprising a light chain, a linker and a heavy chain, wherein the linker is a modified linker comprising an heterologous amino acid sequence which confers at least one physicochemical property to the polypeptide which allows for separation of partially processed and/or unprocessed neurotoxin polypeptides from processed neurotoxin polypeptides, said heterologous amino acid sequence being flanked N- and C-terminally by a protease recognition and cleavage site Further encompassed by the present invention are vectors and host cells comprising the polynucleotide of the invention as well as polypeptides encoded by the polynucleotide and methods for the manufacture of processed neurotoxin polypeptide. | 06-20-2013 |
20130158124 | 1-AMINO-ALKYLCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF MAST CELL MEDIATED DISEASES - The present invention relates to the treatment of an individual afflicted with mast cell mediated diseases comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative. | 06-20-2013 |
20130156747 | PEGylated Mutated Clostridium botulinum Toxin - The invention relates to a modified botulinum toxin comprising a natural heavy chain and a modified light chain, characterized in that the modification of the light chain resides in that it comprises (i) an extension of the chain on its N-terminus which has the structure —(C) | 06-20-2013 |
20130150449 | 1-AMINO-ALKYLCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF INFLAMMATORY SKIN DISEASES - The present invention relates to the treatment of an individual afflicted with inflammatory skin diseases comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative. | 06-13-2013 |
20130143869 | USE OF A CATIONIC AMPHIPHILIC DRUG FOR THE PREPARATION OF A FORMULATION FOR THE REDUCTION OF SUBCUTANEOUS ADIPOSE TISSUE - Use of a cationic amphiphilic drug for the preparation of a formulation for the reduction and/or prevention of subcutaneous adipose tissue with improved effectiveness and better reproducible activity. | 06-06-2013 |
20130142870 | NERAMEXANE MULTIPLE UNIT DOSAGE FORM - Unit comprising neramexane, a pharmaceutically acceptable salt, solvate, conjugate, prodrug, polymorphic form, isomer, or derivative thereof; and a release-controlling excipient; wherein said unit has a diameter of from 0.1 to less than 6 mm. | 06-06-2013 |
20130123541 | METHOD OF PREPARING 3,3,5,5-TETRAMETHYLCYCLOHEXANONE - Method of preparing 3,3,5,5-tetramethylcyclohexanone comprising step (i): (i) converting isophorone to 3,3,5,5-tetramethylcyclohexanone in the presence of methylmagnesium chloride. The thus prepared 3,3,5,5-tetramethylcyclohexanone may be employed in a method of preparing 1-amino-1,3,3,5,5-pentamethylcyclohexane (Neramexane) or a pharmaceutically acceptable salt thereof. | 05-16-2013 |
20130121987 | THERAPEUTIC COMPOSITION WITH A BOTULINUM NEUROTOXIN - The present invention pertains to pharmaceutical compositions which comprise a botulinum neurotoxin from | 05-16-2013 |
20130090306 | CHITOSAN BEADS AND FILLER COMPRISING SUCH BEADS - The present invention pertains to chitosan beads consisting of chitosan cross-linked with citrate ions. The present invention furthermore pertains to a filler comprising such chitosan-citrate beads. In one embodiment of the instant invention the filler is a dermal filler. In one further embodiment of the present invention the dermal filler is for the treatment of wrinkles and/or folds. In another embodiment of the instant invention the filler is for use in the treatment of a medical condition. The filler provided in the present invention may further comprise one or more active pharmaceutical ingredients. Further, the present invention pertains to a process for preparing the filler as claimed herein. | 04-11-2013 |
20130089585 | FILLER COMPRISING BEADS - The present invention pertains to a filler comprising beads wherein said beads comprise a polyanionic biopolymer and divalent cations and wherein said polyanionic biopolymer is not alginate. Further, the present invention pertains to a process for manufacturing the claimed filler, and to an injection device comprising the filler. | 04-11-2013 |
20130022992 | IN VITRO ASSAY FOR QUANTIFYING CLOSTRIDIAL NEUROTOXIN ACTIVITY - Novel methods for determining the unknown biological activity of a clostridial neurotoxin in a sample with respect to the known biological activity of a clostridial neurotoxin in a reference sample, comprising the step of comparing the biological activity of a clostridial neurotoxin preparation with the biological activity of a standard preparation of a reference clostridial neurotoxin in certain in vitro systems. | 01-24-2013 |
20120245391 | METHOD OF PREPARING NERAMEXANE OR A SALT THEREOF - Method of preparing 1-amino-1,3,3,5,5-pentamethylcyclohexane or a pharmaceutically acceptable salt thereof (Neramexane), comprising step (iv):
| 09-27-2012 |
20120238631 | COMPOSITIONS COMPRISING CYCLOHEXYLAMINES AND AMINOADAMANTANES - The invention is directed to formulations of pharmaceutical compounds, such as the Cyclohexylamines and Aminoadamantanes which have antimicrobial properties. In particular, it is directed to aqueous based formulations with reduced amounts of preservatives which allow safe and convenient administration and flexible dosing and which, in the case of oral formulations, are easy to swallow. Optionally, the compositions contain components that provide the requisite stability and shelf life while reducing or avoiding incrustation of the composition around the container closure which leads to leaks and difficulty in opening the container. | 09-20-2012 |
20120214182 | SYSTEM FOR DETERMINING UNPROCESSED AND PARTIALLY PROCESSED NEUROTOXIN TYPE A - The present invention is concerned with tools for the quality control and safety during manufacture of neurotoxins. In particular, it relates to a method for the determination of the amount of partially processed and/or unprocessed Botulinum neurotoxin A polypeptide (BoNT/A) in a solution comprising processed and partially processed and/or unprocessed BoNT/A comprising the steps of contacting a sample of the solution with a capture antibody which specifically binds to the partially processed and unprocessed BoNT/A under conditions which allow for binding of the antibody to the partially processed and unprocessed BoNT/A, whereby a complex is formed, and determining the amount of the formed complex, whereby the amount of the complex is indicative for the amount of the partially processed and/or unprocessed BoNT/A in the solution. Moreover, the present invention contemplates a device and a kit for carrying out the method. | 08-23-2012 |
20120190690 | ELTOPRAZINE FOR THE TREATMENT OF WEIGHT DISORDERS - The present invention relates to the treatment of an individual afflicted with a weight disorder, particularly obesity, the instant treatment comprising administering to the individual an effective amount of eltoprazine or a pharmaceutically acceptable salt thereof. | 07-26-2012 |
20120178742 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS - The invention relates to heterocyclic derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders. | 07-12-2012 |
20120136005 | ELTOPRAZINE FOR THE TREATMENT OF ANXIETY - The present invention relates to the treatment of an individual afflicted with certain forms of anxiety, the instant treatment comprising administering to the individual an effective amount of eltoprazine or a pharmaceutically acceptable salt thereof | 05-31-2012 |
20120130130 | METHOD OF PREPARING NERAMEXANE - The method of producing a salt of 1-amino-1,3,3,5,5-pentamethylcyclohexane comprising steps (i) to (v):
| 05-24-2012 |
20120123166 | METHOD OF PREPARING 1-HYDROXY-1,3,3,5,5-PENTAMETHYLCYCLOHEXANE - Method of preparing 1-hydroxy-1,3,3,5,5-pentamethylcyclohexane comprising step (ii): (ii) converting 3,3,5,5-tetramethylcyclohexanone to 1-hydroxy-1,3,3,5,5-pentamethylcyclohexane by using methylmagnesium chloride. 1-hydroxy-1,3,3,5,5-pentamethylcyclohexane may be used for preparing 1-amino-1,3,3,5,5-pentamethylcyclohexane (Neramexane) or a pharmaceutically acceptable salt thereof. | 05-17-2012 |
20120116125 | METHOD OF PREPARING NERAMEXANE - Method of preparing 1-amino-1,3,3,5,5-pentamethylcyclohexane or pharmaceutically acceptable salt thereof, comprising at least two steps selected from the following steps (i) to (iv):
| 05-10-2012 |
20120107362 | NEUROTOXINS EXHIBITING SHORTENED BIOLOGICAL ACTIVITY - The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a neurotoxin polypeptide exhibiting a reduced duration of the biological effect in a subject, wherein the polypeptide comprises at least one degradation signal in the light chain of the neurotoxin polypeptide as well as vectors and host cells comprising the polynucleotide, polypeptides encoded thereby and antibodies specifically binding to the polypeptides. Moreover, the invention relates to medicaments comprising the polynucleotides and polypeptides, as well as specific therapeutic applications thereof. Furthermore, the present invention contemplates methods for the manufacture of the polypeptides and medicaments. | 05-03-2012 |
20120101172 | LIQUID OR POURABLE PROTEOSOME-FORMING BATH AND SHOWER CONCENTRATES, GALENIC APPLICATION PRODUCTS THEREOF, AND THEIR USE - The invention relates to balneological preparations, especially bath and shower preparations, which, as a pourable or liquid premixture concentrate, contain liposome-forming components, such as phospholipids, in addition to natural and/or synthetic lipids, and are also provided as mixtures containing primarily vegetable proteins, surfactants, and optional additives. When entering in contact with an excess of water, the stable systems directly form skin-active proteoliposomes having a catalytic activity for enhancing transfer of active ingredients into the skin. The stable systems can be used directly or in diluted or solid forms of application (such as lipid-containing proteasome shower preparation, proteasome bath powder, and the like). | 04-26-2012 |
20120093866 | FORMULATION FOR STABILIZING PROTEINS, WHICH IS FREE OF MAMMALIAN EXCIPIENT - The present invention pertains to a formulation comprising a hydrophilic polymer, a mixture of a polyalcohol and a sugar, wherein the weight ratio of polyalcohol to sugar is between 2:1 to 5:1 (wt-%), a detergent, and wherein the formulation is free of stabilizing proteins. | 04-19-2012 |
20120088732 | THERAPEUTIC COMPOSITION COMPRISING A BOTULINUM NEUROTOXIN - A pharmaceutical preparation comprising one of the botulinum neurotoxins from | 04-12-2012 |
20120004179 | MEANS AND METHODS FOR MANUFACTURING HIGHLY PURE NEUROTOXIN - The present invention relates to an antibody which specifically binds to unprocessed and/or partially processed neurotoxin polypeptide or an antibody which specifically binds an epitope consisting of a peptide having an amino acid sequence as shown in any one of SEQ ID NOs: 1 to 16 and to methods for the manufacture of such antibodies. Moreover, the present invention relates to a composition comprising processed neurotoxin polypeptide free of unprocessed or partially processed neurotoxin polypeptide and a method for manufacturing said neurotoxin polypeptide based on the antibodies of the invention. The present invention also relates to the use of the aforementioned antibody for separating processed neurotoxin polypeptides from unprocessed or partially processed neurotoxin polypeptides or for determining unprocessed or partially processed neurotoxin polypeptides. The present invention relates to a method for the manufacture of a medicament. | 01-05-2012 |
20110294890 | Neramexane for the treatment or prevention of inner ear disorders - The present invention relates to a method of treatment or prevention of an inner ear disorder in a female comprising administering a therapeutically effective amount of neramexane or a pharmaceutically acceptable salt thereof to a female. | 12-01-2011 |
20110288336 | METHOD FOR PRODUCING MEMANTINE - Method for producing 1-amino-3,5-dimethyladamantane or a salt thereof, comprising: (i) heating 1-formamido-3,5-dimethyladamantane with a base in a protic solvent. | 11-24-2011 |
20110288105 | ELTOPRAZINE FOR THE TREATMENT OF L-DOPA-INDUCED DYSKINESIA - The present invention relates to the treatment of an individual afflicted with L-DOPA-induced dyskinesia, which condition may arise as a consequence of long-term treatment with L-DOPA therapy in Parkinson's patients, the instant treatment comprising administering to the individual an effective amount of eltoprazine or a pharmaceutically acceptable salt thereof. | 11-24-2011 |
20110282100 | PROCESS FOR PREPARING MEMANTINE - The present invention relates to a process for preparing memantine, or a pharmaceutically acceptable salt thereof (e.g., memantine hydrochloride), which is substantially free of impurities. | 11-17-2011 |
20110263900 | PROCESS FOR MANUFACTURING ADAMANTANE DERVATIVES WITH HIGH YIELD - The present invention pertains to process for the amidation of a substituted 1-bromo-adamantane comprising a step (0) of reacting a substituted adamantane with an excess of bromine to obtain a 1-bromo-adamantane and a step (i) of reacting said substituted 1-bromo-adamantane with an amide, wherein the substituted 1-bromo-adamantane is used in the form of a mixture comprising bromine as obtained in step (0), wherein in step (0) a bromine:substituted adamantane molar ratio of from [2.5:1] to less than [5:1] is employed. | 10-27-2011 |
20110250270 | Compositions containing a capillary-active system with application-relevant diffferentiability and their use - A composition that has a capillary-active system C optionally containing a capillary activator system CA consisting of drugs that increase blood flow, stabilize the vascular wall, and/or dilate the blood vessels; and/or a capillary-protective system CP comprising drugs for endothelial stabilization, lipoprotein protection, and for stabilization of leukocytes/platelets; and/or a capillary energy supply system CE comprising redox systems and cofactors in energy provision and energy carriers. This system C is combined with a selective action system S. The compositions are useful, systemically or enterally, especially for the selective control, for example, of structural changes, functional disturbances of the target organs in question (hair, skin, cerebrum, skeleton, muscles, gastrointestinal tract, eyes) as supplements (food supplements, supplementary balanced diet, dietary components), or pharmaceutical agents. | 10-13-2011 |
20110217287 | Therapeutic composition comprising a botulinum neurotoxin - A pharmaceutical preparation comprising one of the botulinum neurotoxins from | 09-08-2011 |
20110212956 | Pyrazolopyrimidines for treating CNS disorders - Substituted pyrazolopyrimidine derivatives of formula (I) | 09-01-2011 |
20110200664 | LIPOSOMAL STRUCTURES FORMING ISOMETRIC AGGLOMERATES, ESPECIALLY BATH BEADS, THE PRODUCTION AND USE THEREOF - The present invention relates to isometric agglomerates of an essentially spherically shaped form, especially bath beads, and the cosmetic, therapeutic and hygienic use thereof. The invention is especially concerned with agglomerates on the basis of carriers of natural origin such as collagen, gelatine, starch, cellulose or urea, which comprise both lipids and vesicle forming agents as well as emulsifying components and optionally additives, without impairing the stability or activity thereof. The agglomerates when contacting water, especially in a bathing, will form liposomal mono- up to multi-layer structures thereby enabling an improved transport of active compounds. This will result in an improved balneological/or therapeutic action as well as a caring effect in the sense of a reconstruction of the skin barrier function. | 08-18-2011 |
20110189158 | CLOSTRIDIAL NEUROTOXINS WITH ALTERED PERSISTENCY - The invention relates to a polypeptide comprising:
| 08-04-2011 |
20110178179 | 1-AMINO-ALKYLCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF COGNITIVE IMPAIRMENT IN TINNITUS - The present invention relates to the treatment of an individual afflicted with cognitive impairment associated with tinnitus comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative. | 07-21-2011 |
20110091503 | Therapeutic composition with a botulinum neurotoxin - The present invention pertains to pharmaceutical compositions which comprise a botulinum neurotoxin from | 04-21-2011 |
20110086916 | INTERVAL THERAPY FOR THE TREATMENT OF TINNITUS - The present invention relates to interval and/or maintenance therapy employing 1-amino-alkylcyclohexane derivatives (e.g., neramexane or a pharmaceutically acceptable salt thereof) for the treatment of an individual afflicted with tinnitus. | 04-14-2011 |
20110077304 | 1-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF COCHLEAR TINNITUS. - The present invention relates to the treatment of an individual afflicted with cochlear tinnitus comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative. | 03-31-2011 |
20110039942 | TITRATION PACKAGE - The present invention relates to a titration package for providing at least one pharmaceutical composition in at least two different dosages. The titration package comprises at least two sets. Each set comprises at least three individually addressable regions. Each addressable region preferably comprises or is represented by a pharmaceutical composition, preferably a tablet. The dosage of the pharmaceutical composition is the same within each of the at least two sets (“common dosage”), while the dosages of the pharmaceutical compositions are different for one of the at least two sets compared to at least one other of the at least two sets. The arrangement of the at least two sets is not a matrix-like arrangement. | 02-17-2011 |
20110034563 | COMPARTMENT-SPECIFIC PLANT EXTRACT COMBINATION OF GINKGO BILOBA EXTRACT AND GINSENG EXTRACT HAVING A TANDEM EFFECT - The invention relates to a plant extract combination of | 02-10-2011 |
20110003820 | PYRAZOLOPYRIMIDINES, A PROCESS FOR THEIR PREPARATION AND THEIR USE AS MEDICINE - The invention relates to pyrazolopyrimidine derivatives as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders. | 01-06-2011 |
20100331259 | USE OF A NEUROTOXIC COMPONENT OF A CLOSTRIDIUM BOTULINUM TOXIN COMPLEX TO REDUCE OR PREVENT SIDE EFFECTS. - Use of a neurotoxic component of a | 12-30-2010 |
20100298442 | 1-Amino-alkyl-cyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists - Certain 1-aminoalkylcyclohexanes are systematically-active 5HT3 and nicotinic receptor antagonists and are useful in the inhibition of progression of or alleviation of conditions resulting from disturbances of serotoninergic or nicotinergic transmission giving them a wide range of utility in the treatment of CNS-disorders. Pharmaceutical compositions thereof for such purpose and method of making same, as well as a method-of-treating conditions which are alleviated by the employment of a 5HT3 or neuronal nicotinic receptor antagonist. | 11-25-2010 |
20100298441 | TITRATION PACKAGE FOR NERAMEXANE AND ITS USE IN THE TREATMENT OF AN INNER EAR DISORDER - The present invention relates to a titration scheme for the administration of a 1-amino-alkylcyclohexane derivative which allows for quick attainment of an effective dose of a 1-amino-alkylcyclohexane derivative while minimizing side effects. The present invention further relates to a titration package for providing a 1-amino-alkylcyclohexane derivative (e.g., neramexane or a pharmaceutically acceptable salt thereof) in at least two different dosages. The present titration scheme/titration package may be useful in the treatment of various diseases, including tinnitus. | 11-25-2010 |
20100298440 | 1-AMINOCYCLOHEXANE DERIVATIVES FOR THE TREATMENT OF HEARING LOSS - The present invention relates to the treatment of an individual diagnosed with hearing loss comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative. | 11-25-2010 |
20100247689 | Agent containing fat (oil), which contains onion extract, the production and use thereof for caring, preventing or treating damaged skin tissue, especially scarred tissue - The invention relates to a novel agent containing fat (oil), which contains onion extract, in addition to the production and use thereof for caring, preventing or treating damaged skin tissue, such as after operations, biopsies, wounds, burns and other accidents, and especially scarred tissue, stretch marks, degenerative skin conditions and others. The agent is characterised in that the base thereof is based on oil, which can be used to produce, for example, cream, lotion, fluid, massage, or balm based products which contain fail (oil). Surprisingly, the onion extract, which contains water, alcohol or water-alcohol, can be integrated into a base containing oil without the effectiveness thereof being reduced or a phase separation being produced. The effectiveness thereof could be proved when the medical application thereof was monitored. | 09-30-2010 |
20100234358 | NERAMEXANE FOR THE TREATMENT OF NYSTAGMUS - The present invention relates to the treatment of an individual diagnosed with nystagmus comprising administering to the individual an effective amount of a 1-aminoalkylcyclohexane derivative, for example neramexane or a pharmaceutically acceptable salt thereof, such as neramexane mesylate. | 09-16-2010 |
20100227852 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase inhibitors - The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine. | 09-09-2010 |
20100197792 | 1-Amino-Alkylcyclohexane derivatives for the treatment of inflammatory skin diseases - The present invention relates to the treatment of an individual afflicted with inflammatory skin diseases comprising administering to the individual an effective amount of a 1-amino-alkylcyclohexane derivative. | 08-05-2010 |
20100190751 | NOVEL COMBINATION OF NERAMEXANE FOR TREATMENT OF NERORDEGENERATIE DISORDERS - The present invention relates to combinations comprising neramexane and a Glutamate Release Inhibitor (GRI) and the use of such combinations in the treatment of neurodegenerative disorders. | 07-29-2010 |
20100098766 | USE OF AN AQUEOUS MICRO-EMULSION FOR THE PREPARATION OF A FORMULATION FOR THE TREATMENT OF ADIPOSE DISEASES - Use of a micro-emulsion comprising at least one surfactant having a HLB value between 5 and 15, at least one lipophilic substance, and water for the preparation of a formulation for the treatment of adipose tissue disease and/or condition with improved bioavailability and good release behaviour of active substances. | 04-22-2010 |
20100076073 | Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders - The present invention provides a method for the treatment of depression, including treatment-resistant depression, and other mood disorders using a combination of an NMDA receptor antagonist and a SSRI that is citalopram or escitalopram. It has unexpectedly been shown that the combination has a synergistic and potentiated effect of either compound as monotherapy, resulting in an enhanced therapeutic effect at lower doses. | 03-25-2010 |
20100035995 | Compositions comprising Cyclohexylamines and Aminoadamantanes - The invention is directed to formulations of pharmaceutical compounds, such as the Cyclohexylamines and Aminoadamantanes which have antimicrobial properties. In particular, it is directed to aqueous based formulations with reduced amounts of preservatives which allow safe and convenient administration and flexible dosing and which, in the case of oral formulations, are easy to swallow. Optionally, the compositions contain components that provide the requisite stability and shelf life while reducing or avoiding incrustation of the composition around the container closure which leads to leaks and difficulty in opening the container. | 02-11-2010 |
20100004216 | Medicinal lipolysis of accumulation of fat - Aqueous preparations comprising at least one phospholipid or at least one bile acid and a component assisting degradation of fat such as riboflavin and water are suitable for producing medicaments for removing subcutaneous accumulations of fat and lead to regression of diet-resistant fat pads. | 01-07-2010 |
20090299097 | Method for Producing 1-Formamido-3,5-Dimethyladamantane - The invention relates to a method for producing 1-formamido-3,5-dimethyladamantane in only two reaction steps by direct formamide formation of 1,3-dimethyladamantane, the 1,3-dimethyladamantane being reacted with formamide in concentrated acids. | 12-03-2009 |
20090124659 | Combination therapy using 1-aminocyclohexane derivatives and acetylcholinesterase and inhibitors - The invention relates to a novel drug combination therapy useful in the treatment of dementia comprising administering an 1-aminocyclohexane derivative such as memantine or neramexane and an acetylcholinesterase inhibitor (AChEI) such as galantamine, tacrine, donepezil, or rivastigmine. | 05-14-2009 |
20090081259 | 1-Aminocyclohexane derivatives for the treatment of multiple sclerosis, emotional lability and pseudobulbar affect - The present invention relates to the treatment of individuals diagnosed with multiple sclerosis, emotional lability or pseudobulbar affect comprising administering to said individual an effective amount of a 1-aminocyclohexane derivative, namely memantine or neramexane. | 03-26-2009 |
20090028906 | Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin in a solid form - The present invention relates to a method for providing a muscle relaxant at temperatures above 20° C., wherein said muscle relaxant is a solid dry composition comprising the neurotoxic component of botulinum toxin free of complexing proteins. | 01-29-2009 |
20090010965 | Process for providing a temperature-stable muscle relaxant on the basis of the neurotoxic component of botulinum toxin - The present invention provides a method for providing a muscle relaxant, wherein said muscle relaxant is a reconstituted solution comprising the neurotoxic component of botulinum toxin free of complexing proteins, which exhibits at least one of the following characteristics, more preferably all characteristics a) to d):
| 01-08-2009 |
20080279896 | Treatment of movement disorders by a combined use of chemodenervating agent and automated movement therapy - The present invention relates to a method of treating a movement disorder in a patient, the method comprising administering a medicament comprising an effective amount of chemodenervating agent to the patient, wherein the patient is subjected to a muscle stimulation therapy, for example an movement therapy or an muscle activation therapy, and the medicament is administered prior to and/or during and/or after the movement therapy and a kit for the treatment of patients suffering from movement disorders comprising a medicament comprising an effective amount of a chemodenervating agent, and a device for carrying out automated movement therapy. | 11-13-2008 |
20080268055 | Use of an aqueous micro-emulsion for the preparation of a formulation for the treatment of adipose diseases - A method for treating a patient suffering from an adipose tissue disease and/or a condition associated with adipose tissue disease, comprising administering a micro-emulsion comprising at least one surfactant having a HLB value between 5 and 15, at least one lipophilic substance, and water in an amount effective for treatment of the disease and/or condition. | 10-30-2008 |